News

PipelineReview.com12h
Precirix Announces FDA Acceptance of Investigational New Drug (IND) Application for CAM-FAP-Ac-225
BRUSSELS, Belgium I July 24, 2025 I Precirix, a clinical-stage biopharmaceutical company focused on developing innovative targeted radiopharmaceutical ...
PipelineReview.com14h
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with ...
PipelineReview.com15h
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
PARIS, France I July 25, 2025 I Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, ...
PipelineReview.com14h
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
SCHLIEREN / ZURICH, Switzerland I July 25, 2025 I Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior ...
PipelineReview.com14h
GNT Pharma Receives Regulatory Approval to Initiate Multinational Phase 3 Clinical Trials for its Breakthrough Stroke Therapy ‘ Nelonemdaz™
NEW YORK, NY, USA I July 24, 2025 I GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND ...
PipelineReview.com14h
Novavax’s H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
GAITHERSBURG, MD, USA I July 24, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic ...
PipelineReview.com14h
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, France I July 24, 2025 I Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable ...
PipelineReview.com14h
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), ...
PipelineReview.com1d
Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea
CAMBRIDGE, MA, USA I July 23, 2025 I Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that ...
PipelineReview.com1d
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of ...
PipelineReview.com1d
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
MENLO PARK, CA, USA & GENEVA, Switzerland I July 23, 2025 I AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs ...
PipelineReview.com1d
Windward Bio Initiates Global Phase 2 Asthma Trial of WIN378, a Potential Best-in-Disease, Long-Acting, Anti-TSLP Monoclonal Antibody
BASEL, Switzerland I July 23, 2025 I Windward Bio AG, a private, clinical-stage biotechnology company committed to improving outcomes for people living with ...